Delivery Order SPE2DB20D3505-SPE2DB24FV0U0

Award Date 9/24/24
Potential Completion Date 9/25/24
Potential Value $6.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $6,306.12, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ondansetron HCL 8 mg tablets in 30-count packages. It is a firm-fixed-price delivery order with a completion date of January 8, 2025. The contract is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen holds a significant...
This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is a delivery order valued at $8,905.16 for the supply of 8 mg ondansetron hydrochloride tablets. The award was made by the Defense Logistics Agency (DLA), a defense agency, and has a completion date of January 30, 2023. The contract is a firm-fixed-price type with no set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,182.40 firm fixed-price delivery order is for the supply of 4,565,098,253 units of ondansetron HCL 8 mg tablets. The award does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,683.96 firm fixed-price delivery order is for the supply of 4,560 units of 8mg Ondansetron HCL tablets. The contract has a completion date of February 24, 2023 and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,614.43 firm fixed-price delivery order is for the supply of Ondansetron ODT 8 mg tablets. The contract has a period of performance through January 22, 2024 and is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, valued at $3,432.99, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of 8 mg Ondansetron Hydrochloride tablets, a medication used to prevent nausea and vomiting. This order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,229.66 firm fixed-price delivery order is for the supply of 4 mg ondansetron hydrochloride tablets in 30-count packages. The contract has a completion date of January 13, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,473.19 contract is a Firm Fixed Price Delivery Order for the provision of Ondansetron HCL 8 mg tablets. This contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,185.10 Firm Fixed Price delivery order is for the supply of 4,568,163,603 units of ondansetron hydrochloride 8 mg tablets. The contract has an ultimate completion date of May 7, 2025 and is not set aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,589.89 firm fixed-price delivery order is for the provision of 4,567,437,179 units of Ondansetron HCL 8 mg tablets. The contract has an ultimate completion date of March 4, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
  • SPE2DB20D3505
    Indefinite Delivery Contract
  • SPE2DB20D3505-SPE2DB24FV0U0
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $6,258.90, is for the delivery of ondansetron hydrochloride 8 mg tablets.

The contract is a delivery order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

The contract does not have a set-aside designation, indicating open competition. In addition to the DLA contract, AmerisourceBergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.

Generated 2/27/25, 11:15 AM